Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2019

Open Access 01-06-2019 | Breast Cancer | Clinical trial

Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study

Authors: R. Wuerstlein, R. Kates, O. Gluz, E. M. Grischke, C. Schem, M. Thill, S. Hasmueller, A. Köhler, B. Otremba, F. Griesinger, C. Schindlbeck, A. Trojan, F. Otto, M. Knauer, R. Pusch, N. Harbeck, WSG-PRIMe investigators in Germany, Austria, Switzerland

Published in: Breast Cancer Research and Treatment | Issue 2/2019

Login to get access

Abstract

Purpose

The WSG-PRIMe Study prospectively evaluated the impact of the 70-gene signature MammaPrint® (MP) and the 80-gene molecular subtyping assay BluePrint® on clinical therapy decisions in luminal early breast cancer.

Methods

452 hormone receptor (HR)-positive and HER2-negative patients were recruited (N0, N1). Physicians provided initial therapy recommendations based on clinicopathological factors. After prospective risk classification by MammaPrint/BluePrint was revealed, post-test treatment recommendations and actual treatment were recorded. Decisional Conflict and anxiety were measured by questionnaires.

Results

Post-test switch (in chemotherapy (CT) recommendation) occurred in 29.1% of cases. Overall, physician adherence to MP risk assessment was 92.3% for low-risk and 94.3% for high-risk MP scores. Adherence was remarkably high in “discordant” groups: 74.7% of physicians initially recommending CT switched to CT omission following low-risk MP scores; conversely, 88.9% of physicians initially recommending CT omission switched to CT recommendations following high-risk MP scores. Most patients (99.2%) recommended to forgo CT post-test and 21.3% of patients with post-test CT recommendations did not undergo CT; among MP low-risk patients with pre-test and post-test CT recommendations, 40% did not actually undergo CT. Luminal subtype assessment by BluePrint was discordant with IHC assessment in 34% of patients. Patients’ State Anxiety scores improved significantly overall, particularly in MP low-risk patients. Trait Anxiety scores increased slightly in MP high risk and decreased slightly in MP low-risk patients.

Conclusions

MammaPrint and BluePrint test results strongly impacted physicians’ therapy decisions in luminal EBC with up to three involved lymph nodes. The high adherence to genetically determined risk assessment represents a key prerequisite for achieving a personalized cost-effective approach to disease management of early breast cancer.
Literature
1.
van’t Veer LJ, Bernards R (2008) Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 452(7187):564–570CrossRef
2.
Gupta A, Mutebi M, Bardia A (2015) Gene-expression-based predictors for breast cancer. Ann Surg Oncol 22:3418–3432CrossRefPubMed
3.
Drukker CA, Bueno-de-Mesquita JM, Retel VP et al (2013) A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. Int J Cancer 133(4):929–936CrossRefPubMedPubMedCentral
4.
van ‘t Veer LJ, Dai H, van de Vijver MJ et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871):530–536CrossRefPubMed
5.
van de Vijver MJ, He YD, van’t Veer LJ et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347(25):1999–2009CrossRefPubMed
6.
Krijgsman O, Roepman P, Zwart W, Carroll JS, Tian S, de Snoo FA et al (2012) A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response. Breast Cancer Res Treat 133(1):37–47CrossRefPubMed
7.
Gluck S, de Snoo F, Peeters J, Stork-Sloots L, Somlo G (2013) Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy. Breast Cancer Res Treat 139(3):759–767CrossRefPubMed
8.
Goldhirsch A, Winer EP, Coates AS et al (2013 Sep) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol 24(9):2206–2223CrossRefPubMedPubMedCentral
9.
Buyse M, Loi S, van’t Veer L et al (2006) Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98(17):1183–1192CrossRefPubMed
10.
Bueno-de-Mesquita JM, Linn SC, Keijzer R et al (2009) Validation of 70-gene prognosis signature in node-negative breast cancer. Breast Cancer Res Treat 117(3):483–495CrossRefPubMed
11.
Ishitobi M, Goranova TE, Komoike Y, Motomura K, Koyama H, Glas AM,et al (2010) Clinical utility of the 70-gene MammaPrint profile in a Japanese population. Jpn J Clin Oncol 40(6):508–512CrossRefPubMed
12.
Mook S, Schmidt MK, Viale G, Pruneri G, Eekhout I, Floore A et al (2009) The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1–3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat 116(2):295–302CrossRefPubMed
13.
Mook S, Schmidt MK, Weigelt B, Kreike B, Eekhout I, van de Vijver MJ,et al (2010) The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. Ann Oncol 21(4):717–722CrossRefPubMed
14.
Wittner BS, Sgroi DC, Ryan PD, Bruinsma TJ, Glas AM, Male A et al (2008) Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort. Clin Cancer Res 14(10):2988–2993CrossRefPubMedPubMedCentral
15.
Cardoso F, Van’t Veer LJ, Bogaerts J et al (2016) 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 375(8):717–729CrossRefPubMed
16.
Cusumano PG, Generali D, Ciruelos E et al (2014) European inter-institutional impact study of MammaPrint. Breast 23(4):423–428CrossRefPubMed
17.
Exner R, Bago-Horvath Z, Bartsch R et al (2014) The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER-positive, HER2-negative early breast cancer. Br J Cancer 111(5):837–842CrossRefPubMedPubMedCentral
18.
Pohl H, Kotze MJ, Grant KA et al (2016) Impact of MammaPrint on clinical decision-making in South African patients with early-stage breast cancer. Breast J 22(4):442–446CrossRefPubMed
19.
Tsai M, Lo S, Audeh W, Qamar R, Budway R, Levine E, Whitworth P, Mavromatis B, Zon R, Oldham D, Untch S, Treece T, Blumencranz L, Soliman H (2018) Association of 70-gene signature assay findings with physicians’ treatment guidance for patients with early breast cancer classified as intermediate risk by the 21-gene assay. Jama Oncol 4(1):e173470. https://​doi.​org/​10.​1001/​jamaoncol.​2017.​3470 CrossRefPubMed
20.
Kuijer A, Straver M, den Dekker B, Van Bommel ACM, Elias SG, Smorenburg C, Wesseling J, Linn S, Rutgers EJT, Siesling S, Van Dalen T (2017) Impact of 70-gene signature use on adjuvant chemotherapy decisions in patients with estrogen receptor–positive early breast cancer: results of a prospective cohort study. J Clin Oncol 35:2814CrossRefPubMed
21.
22.
23.
Krijgsman O, Roepman P, Zwart W, Carroll JS, Tian S, de Snoo FA, Bender RA, Bernards R (2012) Glas AM A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response. Breast Cancer Res Treat 133:37–47CrossRefPubMed
24.
25.
26.
Whitworth P, Stork-Sloots L, de Snoo FA (2014) et. al. Chemosensitivity predicted by BluePrint 80-gene functional subtype and MammaPrint in the prospective neoadjuvant breast registry symphony trial (NBRST). Ann Surg Oncol 21:3261–3267CrossRefPubMedPubMedCentral
27.
28.
Yao K, Goldschmidt R, Turk M, Wesseling J, Stork-Sloots L, de Snoo F, Cristofanilli M (2015) Molecular subtyping improves diagnostic stratification of patients with primary breast cancer into prognostically defined risk groups. Breast Cancer Res Treat 154(1):81–88CrossRefPubMedPubMedCentral
29.
Cardoso F, Slaets L, de Snoo F, Bogaerts J, van ‘t Veer LJ, Rutgers EJ, Piccart-Gebhart MJ, Stork-Sloots L, Russo L, Dell’Orto P, Viale G (2017) Can surrogate pathological subtyping replace molecular subtyping? Outcome results from the MINDACT trial. Cancer Res 77(4):PD7
Metadata
Title
Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study
Authors
R. Wuerstlein
R. Kates
O. Gluz
E. M. Grischke
C. Schem
M. Thill
S. Hasmueller
A. Köhler
B. Otremba
F. Griesinger
C. Schindlbeck
A. Trojan
F. Otto
M. Knauer
R. Pusch
N. Harbeck
WSG-PRIMe investigators in Germany, Austria, Switzerland
Publication date
01-06-2019
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2019
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-018-05075-x

Other articles of this Issue 2/2019

Breast Cancer Research and Treatment 2/2019 Go to the issue

Epidemiology

A high-risk luminal A dominant breast cancer subtype with increased mobility

Preclinical study

ERα upregulates the expression of long non-coding RNA LINC00472 which suppresses the phosphorylation of NF-κB in breast cancer

Epidemiology

Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers

Brief report

Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients

Clinical Trial

Adjuvant chemotherapy in lobular carcinoma of the breast: a clinicopathological score identifies high-risk patient with survival benefit

Brief Report

Validation of the breast cancer surveillance consortium model of breast cancer risk
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits